What medication is recommended for treating anxiety in a patient with hypermobile Ehlers‑Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast‑cell activation syndrome (MCAS)?

Medication for Anxiety in hEDS/POTS/MCAS

For anxiety management in patients with hEDS/POTS/MCAS, start with SSRIs (selective serotonin reuptake inhibitors) or SNRIs (serotonin-norepinephrine reuptake inhibitors) as neuromodulators, which serve dual purposes of treating both anxiety and pain symptoms common in this population. 1

Primary Recommendation: Neuromodulators as First-Line

The most recent 2025 AGA guideline explicitly recommends neuromodulators including tricyclic antidepressants, SSRIs, SNRIs, pregabalin, and gabapentin for managing symptoms in hEDS/POTS/MCAS patients 1. These medications address the multisystemic nature of these conditions, particularly the increased rates of anxiety and psychological distress mediated by autonomic dysfunction.

Why This Approach Works:

• Dual benefit: These agents treat both anxiety and the chronic pain that dominates this patient population
• Brain-gut axis: SSRIs/SNRIs address the disordered central processing and visceral hypersensitivity characteristic of these overlapping conditions 1
• Evidence-based: The 2020 AACAP guideline supports SSRIs as first-line pharmacotherapy for anxiety disorders 2

Specific SSRI Selection Strategy

Choose citalopram or escitalopram initially because they have the least effect on CYP450 isoenzymes and lower propensity for drug-drug interactions 2. This is critical in MCAS patients who may be on multiple medications including histamine receptor antagonists and mast cell stabilizers.

Dosing Considerations:

• Start low, go slow: Begin at lower-than-standard doses with gradual up-titration
• Monitor closely: Watch for behavioral activation/agitation, especially in the first month 2
• Avoid paroxetine: Higher risk of suicidal thinking compared to other SSRIs 2
• Citalopram caution: Do not exceed 40 mg/day due to QT prolongation risk 2

Critical Drug Interactions to Avoid

Absolute Contraindications:

• Never combine with MAOIs (including linezolid, isoniazid) - risk of serotonin syndrome 2
• Avoid NSAIDs when possible - increased bleeding risk with SSRIs, and NSAIDs can trigger MCAS 1
• No opioids - explicitly contraindicated for pain management in this population and can trigger mast cell degranulation 1

Medications That Trigger MCAS:

The guideline specifically warns against opioids and NSAIDs as MCAS triggers 1. This makes SSRI/SNRI selection even more important as they provide pain relief without triggering mast cell activation.

Alternative: Atypical Antipsychotics for Treatment-Resistant Cases

If SSRIs/SNRIs fail after adequate trials, consider low-dose risperidone (0.25-1 mg). A 2020 case report demonstrated successful management of treatment-resistant anxiety in an EDS patient with risperidone 3. This addresses both anxiety and the heightened somatic sensation sensitivity in this population.

When to Consider Risperidone:

• Failed trials of at least 2 SSRIs at therapeutic doses for 8-12 weeks
• Severe anxiety interfering with pain management and therapeutic alliance
• No contraindications (avoid in patients with QT prolongation, which may overlap with POTS)

Adjunctive Treatments Required

Simultaneously implement brain-gut behavioral therapies - the guideline emphasizes psychological support as essential, not optional 1. Untreated anxiety increases somatic sensitivity and prevents effective pain management 3.

Address MCAS symptoms concurrently with histamine receptor antagonists (H1 and H2 blockers) and mast cell stabilizers 1. This reduces the inflammatory burden that may worsen anxiety symptoms.

Optimize POTS management with increased fluid/salt intake, compression garments, and exercise training 1. Uncontrolled POTS symptoms (tachycardia, lightheadedness) can mimic and exacerbate anxiety.

Common Pitfalls to Avoid

1. Don't use benzodiazepines chronically - while not explicitly contraindicated, they don't address the underlying pathophysiology and risk dependence in this chronic population

2. Don't dismiss anxiety as "just psychological" - the guideline emphasizes that anxiety in hEDS/POTS/MCAS is mediated by autonomic dysfunction and requires integrated treatment 1

3. Don't start multiple serotonergic agents simultaneously - risk of serotonin syndrome, especially problematic given autonomic instability in POTS 2

4. Don't use stimulants without careful consideration - can worsen POTS symptoms and may have serotonergic effects 1

5. Avoid abrupt discontinuation - paroxetine, fluvoxamine, and sertraline particularly associated with discontinuation syndrome 2

Monitoring Requirements

• First 24-48 hours after initiation or dose changes: Watch for serotonin syndrome symptoms (confusion, agitation, tremors, tachycardia, hypertension) 2
• First month: Monitor for behavioral activation, which should improve with dose reduction 2
• Ongoing: Assess for sexual dysfunction in adolescents/adults, abnormal bleeding, and therapeutic response 2

The integrated approach combining SSRIs/SNRIs with behavioral therapy, MCAS management, and POTS optimization provides the best outcomes for quality of life and functional capacity in this complex patient population 1, 3.